Volume | 29,624 |
|
|||||
News | - | ||||||
Day High | 9.585 | Low High |
|||||
Day Low | 8.72 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
FibroBiologics Inc | FBLG | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
9.54 | 8.72 | 9.585 | 9.43 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
526 | 29,624 | $ 9.10 | $ 269,641 | - | 6.53 - 55.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:23:05 | 1 | $ 8.75 | USD |
FibroBiologics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
286.2M | 32.63M | - | 0 | -19.06M | -0.58 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
FibroBiologics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FBLG Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.91 | 11.70 | 8.60 | 10.61 | 53,418 | -2.15 | -19.69% |
1 Month | 10.89 | 11.75 | 8.60 | 10.72 | 67,104 | -2.13 | -19.55% |
3 Months | 10.25 | 17.75 | 6.53 | 12.02 | 92,528 | -1.49 | -14.52% |
6 Months | 30.00 | 55.00 | 6.53 | 12.48 | 95,743 | -21.24 | -70.80% |
1 Year | 30.00 | 55.00 | 6.53 | 12.48 | 95,743 | -21.24 | -70.80% |
3 Years | 30.00 | 55.00 | 6.53 | 12.48 | 95,743 | -21.24 | -70.80% |
5 Years | 30.00 | 55.00 | 6.53 | 12.48 | 95,743 | -21.24 | -70.80% |
FibroBiologics Description
FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc. |